<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478087</url>
  </required_header>
  <id_info>
    <org_study_id>AMA-2011DCM Pilot Study</org_study_id>
    <nct_id>NCT01478087</nct_id>
  </id_info>
  <brief_title>Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM)</brief_title>
  <official_title>Pilot Study of Immunoadsorption Therapy for Patients With Chronic Non-Ischemic Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asahi Kasei Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asahi Kasei Medical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical safety and feasibility of Mysorba in&#xD;
      patients with chronic non-ischemic dilated cardiomyopathy (DCM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated due to business reasons&#xD;
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Procedure Related Serious Adverse Events (SAE) at 30 Days Post-treatment.</measure>
    <time_frame>30 Days Post Treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Device Related Serious Adverse Events (SAE) at 30 Days Post-treatment.</measure>
    <time_frame>30 days post-treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Cardiomyopathy, Dilated</condition>
  <arm_group>
    <arm_group_label>Mysorba(single-arm)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mysorba</intervention_name>
    <description>Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.</description>
    <arm_group_label>Mysorba(single-arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is 18 years of age or older.&#xD;
&#xD;
          2. Subject has provided written informed consent.&#xD;
&#xD;
          3. Subject has been classified as NYHA Class II or III.&#xD;
&#xD;
          4. Subject has been diagnosed with chronic non-ischemic dilated cardiomyopathy, defined&#xD;
             as left ventricular ejection fraction (LVEF) &lt; 40% and left ventricular end diastolic&#xD;
             dimensions (LVEDd) &gt; 55 millimeters (mm) or LVEDd/BSA &gt; 3.0 cm/m2.&#xD;
&#xD;
          5. Subject was diagnosed with non-ischemic dilated cardiomyopathy ≥ 6 months and ≤ 5&#xD;
             years prior to screening visit.&#xD;
&#xD;
          6. Subject is on stable optimal medical therapy, consisting of ACE inhibitor (or ARB),&#xD;
             β-blocker, and diuretic, for heart failure for at least 3 months&#xD;
&#xD;
          7. Subject and physician agree to switch subject from ACE inhibitors to ARB for the&#xD;
             treatment duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has been classified as NYHA Class I or IV&#xD;
&#xD;
          2. Subject is currently pregnant, lactating, or of child-bearing potential and not taking&#xD;
             adequate birth control as assessed by Investigator.&#xD;
&#xD;
          3. Subject is HBV, HCV or HIV positive.&#xD;
&#xD;
          4. Subject has anemia, defined as hemoglobin &lt; 10.0 g/dL.&#xD;
&#xD;
          5. Subject has compromised renal function as reflected by a serum creatinine level &gt;3.0&#xD;
             mg/dL or eGFR &lt;30 mL/min or is currently on dialysis.&#xD;
&#xD;
          6. Subject has compromised hepatic function as measured by SGPT (ALT) or SGOT (AST) &gt;&#xD;
             three (3) times the upper limit of normal.&#xD;
&#xD;
          7. Subject had acute myocarditis ≤ 3 months prior to screening visit.&#xD;
&#xD;
          8. Subject has a history of diameter stenosis &gt;70% of at least one major coronary artery,&#xD;
             as determined by angiography or CTA obtained within the previous 5 years.&#xD;
&#xD;
          9. Subject is on immunosuppressive or immunomodulation therapy: intravenous (IV),&#xD;
             intramuscular (IM), or oral.&#xD;
&#xD;
         10. Subject has a history of the following pre-existing heart disease:&#xD;
&#xD;
               -  myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary&#xD;
                  artery bypass graft (CABG)&#xD;
&#xD;
               -  valvular heart disease requiring repair, replacement, or balloon valvuloplasty&#xD;
&#xD;
               -  hypertrophic/restrictive cardiomyopathy or constrictive pericarditis&#xD;
&#xD;
         11. Subject is currently participating in, or ≤ 6 months prior to screening visit has&#xD;
             participated in, an investigational study of a new drug, biologic, or device.&#xD;
&#xD;
         12. Subject has left ventricular noncompaction.&#xD;
&#xD;
         13. Subject has a left ventricular assist device (LVAD).&#xD;
&#xD;
         14. Subject has received a heart transplant.&#xD;
&#xD;
         15. Subject has DCM due to any of the following:&#xD;
&#xD;
               -  amyloidosis&#xD;
&#xD;
               -  sarcoidosis&#xD;
&#xD;
               -  connective tissue disease&#xD;
&#xD;
               -  peripartum cardiomyopathy&#xD;
&#xD;
               -  alcoholism&#xD;
&#xD;
               -  endocrine dysfunction as the primary cause of DCM&#xD;
&#xD;
               -  prior illicit drug use which the investigator feels as likely cause for the&#xD;
                  cardiomyopathy&#xD;
&#xD;
               -  hereditary and familial conditions (such as genetic dilated cardiomyopathy,&#xD;
                  familial storage disease, Heredofamilial neurologic and neuromuscular diseases)&#xD;
&#xD;
         16. Subject has undergone cardiac resynchronization therapy ≤ 6 months prior to screening&#xD;
             visit.&#xD;
&#xD;
         17. Subject is unable to take ARB in place of ACE inhibitors.&#xD;
&#xD;
         18. Subject has a history of stroke ≤ 3 months prior to screening visit.&#xD;
&#xD;
         19. Subject currently has severe systemic infection requiring treatment with antibiotics.&#xD;
&#xD;
         20. Subject currently has hemodynamic instability defined as systolic blood pressure &lt; 90&#xD;
             mm Hg without afterload reduction, or cardiogenic shock, or the need for inotropic&#xD;
             support or intra-aortic balloon pump.&#xD;
&#xD;
         21. Subject has previously undergone immunosuppressive or immunomodulation therapy.&#xD;
&#xD;
         22. Subject has known hypersensitivity or contraindication to heparin including history of&#xD;
             heparin induced thrombocytopenia (HIT).&#xD;
&#xD;
         23. Subject has history of drug or alcohol abuse or is currently abusing alcohol or drugs.&#xD;
&#xD;
         24. Subject has active malignancy or tumor, or other non-cardiac medical condition, which&#xD;
             causes life expectancy to be less than one year.&#xD;
&#xD;
         25. History of neutropenia (WBC &lt; 3,000/mm3), coagulopathy, or thrombocytopenia (platelet&#xD;
             count &lt; 100,000/μL) that has not resolved or has required treatment in the past 6&#xD;
             months.&#xD;
&#xD;
         26. Subject weighs less than 40 kg (88 lbs).&#xD;
&#xD;
         27. Subject requires major elective procedures (AHA-defined intermediate to high risk&#xD;
             surgery) within 6 months post-treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Winters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 7, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <results_first_submitted>January 8, 2013</results_first_submitted>
  <results_first_submitted_qc>January 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2013</results_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First site open to enrollment : November 3, 2011 Study terminated: March 22, 2012</recruitment_details>
      <pre_assignment_details>Three (3) subjects enrolled, 2 completed treatment through six-month follow up. One (1) subject terminated participation prior to treatment due to sponsor stopping the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IA Treatment</title>
          <description>The Mysorba device is an immunoadsorbent column. : Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>due to sponsor closing study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IA Treatment</title>
          <description>The Mysorba device is an immunoadsorbent column. : Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Procedure Related Serious Adverse Events (SAE) at 30 Days Post-treatment.</title>
        <time_frame>30 Days Post Treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IA Treatment</title>
            <description>The Mysorba device is an immunoadsorbent column. : Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Procedure Related Serious Adverse Events (SAE) at 30 Days Post-treatment.</title>
          <units>percentage of procedure related SAE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Device Related Serious Adverse Events (SAE) at 30 Days Post-treatment.</title>
        <time_frame>30 days post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IA Treatment</title>
            <description>The Mysorba device is an immunoadsorbent column. : Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Device Related Serious Adverse Events (SAE) at 30 Days Post-treatment.</title>
          <units>percentage of device related SAE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IA Treatment</title>
          <description>The Mysorba device is an immunoadsorbent column. : Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PVC'S</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>loss of vascular access</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>pulse drop</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>elevated INR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizzy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI shall provide the sponsor with a copy of any proposed publication for review at least 60 days prior to submission to a publisher. The sponsor may request that any confidential information or intellectual property contained be removed, redacted, or modified. If the PI do not agree to such deletion or modification, they shall notify the sponsor and agree to postpone such submission for an additional 60 days to allow sponsor to file the appropriate applications or seek protective remedies.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Lawrence Winters, MD</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-538-1707</phone>
      <email>winters.jeffrey@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

